Blanchard Thomas G, Eisenberg Julia C, Matsumoto Yuko
Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Vaccine. 2004 Feb 17;22(7):888-97. doi: 10.1016/j.vaccine.2003.11.035.
Helicobacter pylori vaccine development has progressed rapidly in animal models. Both H. pylori-associated pathogenesis and protective immunity are CD4+ T cell dependent, with no discernable phenotypic difference to distinguish pathogenic T cells from protective T cells. Functionally however, protective T cells promote enhanced inflammation upon H. pylori challenge. Additionally, only mouse models such as phagocyte oxidase- or IL-10-deficient mice that respond to H. pylori infection with intense gastritis are capable of demonstrating spontaneous eradication of the bacteria. These data, combined with recent descriptions of down-regulatory T cells in infected humans and mice, support an emerging model of H. pylori pathogenesis in which H. pylori induces inflammation that is limited by regulatory T cells in the stomach. Immunization therefore may succeed by activating T cells in peripheral lymph nodes that are capable of promoting qualitatively or quantitatively different inflammation when recruited to the stomach. Evidence in support of this model will be discussed.
幽门螺杆菌疫苗的研发在动物模型中进展迅速。幽门螺杆菌相关的发病机制和保护性免疫均依赖于CD4 + T细胞,在区分致病性T细胞和保护性T细胞方面没有明显的表型差异。然而,在功能上,保护性T细胞在幽门螺杆菌攻击时会促进炎症增强。此外,只有诸如吞噬细胞氧化酶或白细胞介素-10缺陷小鼠等对幽门螺杆菌感染产生强烈胃炎反应的小鼠模型才能证明细菌的自发清除。这些数据,结合最近对受感染人类和小鼠中下调性T细胞的描述,支持了一种新兴的幽门螺杆菌发病机制模型,即幽门螺杆菌诱导的炎症在胃中受到调节性T细胞的限制。因此,免疫接种可能通过激活外周淋巴结中的T细胞而成功,这些T细胞在被招募到胃中时能够促进性质或数量上不同的炎症。将讨论支持该模型的证据。